Glycomine focuses on creating medications for severe uncommon metabolic and protein misfolding conditions with no other available treatments. The company's strategy involves utilizing replacement therapies such as substrates, enzymes, or proteins and directing these molecules to relevant cellular compartments. GLM101, Glycomine's primary drug candidate, is a new substrate replacement therapy being developed to address phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease with a crucial unmet medical necessity.